Novartis Signs Gene Therapy Agreement with Voyager for US$ 100 Mn Upfront
Voyager Therapeutics said that the Swiss-based drugmaker Novartis would spend US$ 100 million upfront as part of a licensing contract to create gene therapy candidates for genetic disorders. Voyager, whose shares jumped over 30% in premarket trading, would be suitable to acquire up to US$ 1.2 billion upon attaining specific milestones.
The gene therapy developer would deliver Novartis access to its RNA-based screening platform, which assists in the quick discovery of experimental gene therapies and would also be suitable for tiered royalties on global sales of products developed utilizing the platform. In addition to this, according to the research report of Astute Analytica , the global gene therapy market is growing at a compound annual growth rate (CAGR) of 24% during the forecast period from 2023 to 2030.
The companies would team up to create a pre-clinical gene therapy candidate for Huntington's disease (HD), an inherited disease that causes nerve cells in parts of the brain to break down and die slowly. Voyager would extend the pre-clinical development and Novartis would be accountable for all clinical studies and commercialization for the HD candidate.
Novartis would also get access to the platform Voyager to develop and discover possible gene therapies for treating spinal muscular atrophy. Novartis had once exercised an alternative to license novel capsids or gene therapy delivery vehicles developed from the drug discovery platform of Voyager as a possible treatment for two undisclosed neurological diseases.
Individually, Voyager is creating an investigational gene therapy to treat a neurological condition, amyotrophic lateral sclerosis (ALS), and an antibody for Alzheimer's disease.
领英推荐
?????? ???? ?????????? ???????? ????
?????????? ????????????: +??????????????????????
??????????: [email protected]
?????????? ?????? ??????????????: https://www.astuteanalytica.com/